Adage Capital Partners
TEVA icon

Adage Capital Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Adage Capital Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-534,000
Closed -$8.95M – 976
2025
Q2 		$8.95M Buy
534,000
+50,000
+10% +$807K 0.02% 639
2025
Q1 		$7.44M Sell
484,000
-716,000
-60% -$12.8M 0.01% 640
2024
Q4 		$26.4M Sell
1,200,000
-2,421,899
-67% -$44.1M 0.05% 364
2024
Q3 		$65.3M Buy
3,621,899
+1,518,733
+72% +$26.6M 0.12% 191
2024
Q2 		$34.2M Buy
2,103,166
+1,576,166
+299% +$24.3M 0.06% 302
2024
Q1 		$7.44M Hold
527,000
– – 0.01% 649
2023
Q4 		$5.5M Buy
+527,000
New +$4.92M 0.01% 671
2017
Q4 		– Sell
-250,000
Closed -$4.4M – 748
2017
Q3 		$4.4M Buy
+250,000
New +$5.63M 0.01% 633

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Adage Capital Partners's TEVA Position: Q3 2025 in Review

Adage Capital Partners sold out of Teva Pharmaceuticals (TEVA) in Q3 2025, closing a stake of 534,000 shares — an estimated $8.95M sold.

Adage Capital Partners first reported a position in TEVA in Q3 2017 and held it in 8 quarters. The position peaked at $65.3M in Q3 2024. 550 funds tracked by Wall St. Rank hold TEVA as of Q3 2025.

  • Adage Capital Partners reported no remaining Teva Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Adage Capital Partners sold 534,000 Teva Pharmaceuticals shares in Q3 2025, an estimated $8.95M.
  • Adage Capital Partners first reported a position in Teva Pharmaceuticals in Q3 2017 and held it in 8 quarters.
  • Adage Capital Partners's Teva Pharmaceuticals position peaked at $65.3M in Q3 2024.
  • 550 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2025.

Based on Adage Capital Partners's 13F filing for Q3 2025, filed 14 Nov 2025.